Crinetics Pharmaceuticals, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Vertex Pharmaceuticals completed its acquisition of Crinetics Pharmaceuticals (CRNX), delisting it from Nasdaq. Crinetics is now a subsidiary, with leadership changes announced. The $10B deal was funded by cash, debt, and $4.5B in bridge financing. Vertex gains exposure to Crinetics' endocrine disease treatments. Investors should watch for updates on pipeline and commercial priorities.
Crinetics Pharmaceuticals (CRNX) director Vivaldi Coelho Rogerio reported disposing of stock and options on September 1, 2026, following the company's merger with Vertex Pharmaceuticals. Each Crinetics share was converted into $85.00 in cash. The director's dispositions included common stock, restricted stock units, and stock options, all converted according to the merger terms.
WIERENGA WENDELL sold (to issuer) 122,071 shares of Crinetics Pharmaceuticals, Inc. (CRNX) at $85.00 ($10.38M total) across 2 trades on 2026-09-01.
Over the past 7 days, alphai's AI scored 14 news stories mentioning CRNX (Crinetics Pharmaceuticals, Inc.). Coverage has been balanced: 2 bullish, 10 neutral, and 2 bearish.
Recent CRNX coverage spans insider activity, financial news and mergers & acquisitions.
In the last 30 days, CRNX insiders filed 32 SEC Form 4 transactions — no purchases and 32 sales ($161.9M). The most active reporter was Struthers Richard Scott, President & CEO, with 12 filings.
CRNX shares cease trading; shareholders receive cash at $85 per share.
The insider sale reflects the cash-out from the merger, indicating no further upside for remaining shareholders and confirming the $85 per share merger consideration.
Significant insider sell may signal lack of confidence, potentially pressuring the stock.
The insider sale reduces insider ownership to zero, potentially signaling lack of confidence.
Insider cash-out reflects merger terms; unlikely to move CRNX price significantly.
alphai scores every news story that mentions CRNX with an AI model for sentiment and relevance, and aggregates insider trades from Crinetics Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Vertex Pharmaceuticals completed its acquisition of Crinetics Pharmaceuticals (CRNX), delisting it from Nasdaq. Crinetics is now a subsidiary, with leadership changes announced. The $10B deal was funded by cash, debt, and $4.5B in bridge financing. Vertex gains exposure to Crinetics' endocrine disease treatments. Investors should watch for updates on pipeline and commercial priorities.
2 min readCrinetics Pharmaceuticals (CRNX) director Vivaldi Coelho Rogerio reported disposing of stock and options on September 1, 2026, following the company's merger with Vertex Pharmaceuticals. Each Crinetics share was converted into $85.00 in cash. The director's dispositions included common stock, restricted stock units, and stock options, all converted according to the merger terms.
1 min readWIERENGA WENDELL sold (to issuer) 122,071 shares of Crinetics Pharmaceuticals, Inc. (CRNX) at $85.00 ($10.38M total) across 2 trades on 2026-09-01.
1 min readVivaldi Coelho Rogerio sold (to issuer) 19,225 shares of Crinetics Pharmaceuticals, Inc. (CRNX) at $85.00 ($1.63M total) across 2 trades on 2026-09-01.
1 min readCrinetics Pharmaceuticals (CRNX) director Weston Nichols received $85 per share in cash as part of the company's merger with Vertex Pharmaceuticals. His stock options were canceled, with those below $85 exercise price converted to cash, while others received no consideration. The merger was effective September 1, 2026.
2 min readOkey Stephanie sold (to issuer) 12,325 shares of Crinetics Pharmaceuticals, Inc. (CRNX) at $85.00 ($1.05M total) across 2 trades on 2026-09-01.
1 min readNichols Weston sold (to issuer) 22,225 shares of Crinetics Pharmaceuticals, Inc. (CRNX) at $85.00 ($1.89M total) across 2 trades on 2026-09-01.
1 min readFust Matthew K sold (to issuer) 28,761 shares of Crinetics Pharmaceuticals, Inc. (CRNX) at $85.00 ($2.44M total) across 2 trades on 2026-09-01.
1 min readDeardorf Caren sold (to issuer) 22,225 shares of Crinetics Pharmaceuticals, Inc. (CRNX) at $85.00 ($1.89M total) across 2 trades on 2026-09-01.
1 min readBedrosian Camille L sold (to issuer) 22,225 shares of Crinetics Pharmaceuticals, Inc. (CRNX) at $85.00 ($1.89M total) across 2 trades on 2026-09-01.
1 min read